KHK4951
Asset
Inhibits vascular endothelial growth factor receptors to reduce retinal vascular leakage and edema.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- FLT1
- 2
- Indications
- 2
- Trials
- 1
- Developer
Indications
2Diabetic macular edema
Phase 2, Active not recruiting, NCT06116916, clinicaltrials.gov, 17 Oct 2026
Neovascular age-related macular degeneration
Phase 2, Completed, NCT06116890, clinicaltrials.gov, 16 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials2
- Evidence for its targets3
- Competitors11
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.